Drug intelligence / Profile preview

TR-002

Development stage: Unknown
Lead developer: University of California, Davis
Modality: Small Molecules
Administration: Intravenous

Overview

TR-002 is a bisaminoquinoline derivative being developed by the University of California, Davis. It is currently in Phase 1 clinical trials for the treatment of advanced, unresectable, or metastatic solid tumors, including refractory pancreatic adenocarcinoma. As a chemotherapy agent, TR-002 is designed to inhibit tumor cell growth by inducing cell death, halting cell division, and preventing the spread of cancer cells. The drug is administered via weekly intravenous infusion.

Other names: Bisaminoquinoline derivative

Beyond the preview

Go deeper on TR-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TR-002.

Explore the full profile